Over 12 million people in the United States died from all causes between the beginning of January 2020 and August 21, 2023. Over 1.1 million of those deaths were with confirmed or presumed COVID-19.

Vaccine rollout in the United States Finding a safe and effective COVID-19 vaccine was an urgent health priority since the very start of the pandemic. In the United States, the first two vaccines were authorized and recommended for use in December 2020. One has been developed by Massachusetts-based biotech company Moderna, and the number of Moderna COVID-19 vaccines administered in the U.S. was over 250 million. Moderna has also said that its vaccine is effective against the coronavirus variants first identified in the UK and South Africa.

Influenza and pneumonia caused around 10.9 deaths in the U.S. per 100,000 population in 2023. Influenza, or the flu, is a viral infection that is highly contagious and especially common in the winter season. Influenza is a common cause of pneumonia, although most cases of the flu do not develop into pneumonia. Pneumonia is an infection or inflammation of the lungs and is particularly deadly among young children and the elderly. Influenza cases Influenza is very common in the United States, with an estimated 40 million cases reported in 2023-2024. Common symptoms of the flu include cough, fever, runny or stuffy nose, sore throat and headache. Symptoms can be mild but can also be severe enough to require medical attention. In 2023-2024, there were around 18 million influenza-related medical visits in the United States. Prevention To prevent contracting the flu, people can take everyday precautions such as regularly washing their hands and avoiding those who are sick, but the best way to prevent the flu is by receiving the flu vaccination every year. Receiving a flu vaccination is especially important for young children and the elderly, as they are most susceptible to flu complications and associated death. In 2024, around 70 percent of those aged 65 years and older received a flu vaccine, while only 33 percent of those aged 18 to 49 years had done so.

Pneumonia death rates by county, all races (includes Hispanic/Latino), all sexes, all ages, 2019-2023. Death data were provided by the National Vital Statistics System. Death rates (deaths per 100,000 population per year) are age-adjusted to the 2000 US standard population (20 age groups: <1, 1-4, 5-9, ... , 80-84, 85-89, 90+). Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by the National Cancer Institute. The US Population Data File is used for mortality data. The Average Annual Percent Change is based onthe APCs calculated by the Joinpoint Regression Program (Version 4.9.0.0). Due to data availability issues, the time period used in the calculation of the joinpoint regression model may differ for selected counties. Counties with a (3) after their name may have their joinpoint regresssion model calculated using a different time period due to data availability issues.

The burden of influenza in the United States can vary from year to year depending on which viruses are circulating, how many people receive an influenza vaccination, and how effective the vaccination is in that particular year. During the 2023-2024 flu season, around 28,000 people lost their lives to the disease. Although most people recover from influenza without needing medical care, the disease can be deadly among young children, the elderly, and those with weakened immune systems or chronic illnesses. Deaths due to influenza Even though most people recover from influenza without medical care, influenza and pneumonia can be deadly, especially for older people and those with certain preexisting conditions. Influenza is a common cause of pneumonia and although most cases of influenza do not develop into pneumonia, those that do are often more severe and more deadly. Deaths due to influenza are most common among the elderly, with a mortality rate of around 32 per 100,000 population during the 2023-2024 flu season. In comparison, the mortality rate for those aged 50 to 64 years was 9.1 per 100,000 population. Flu vaccinations The most effective way to prevent influenza is to receive an annual influenza vaccination. These vaccines have proven to be safe and are usually cheap and easily accessible. Nevertheless, every year a large share of the population in the United States still fails to get vaccinated against influenza. For example, in the 2022-2023 flu season, only 35 percent of those aged 18 to 49 years received a flu vaccination. Unsurprisingly, children and the elderly are the most likely to get vaccinated. It is estimated that during the 2022-2023 flu season, vaccinations prevented over 929 thousand influenza cases among children aged 6 months to 4 years.

Context

Corona virus cases in the US is stacking up higher and higher. Understanding this virus is crucial to stopping it's spread.

Content

The dataset shows, deaths involving coronavirus disease 2019 (COVID-19), pneumonia, and influenza reported to NCHS by sex and age group and state.

Acknowledgements

Credits to this data set comes from : https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by-Sex-Age-and-S/9bhg-hcku

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Deaths involving COVID-19, pneumonia, and influenza reported to NCHS by race, age, and jurisdiction of occurrence.

During the 2023-2024 flu season in the United States, an estimated 27,965 people died from influenza. The vast majority of deaths due to influenza occur among the elderly, with those aged 65 years and older accounting for 19,038 deaths during the 2023-2024 flu season. During this time, the mortality rate from influenza among those aged 65 years and older was around 32 per 100,000 population, compared to a mortality rate of two per 100,000 population among those aged 18 to 49 years. Influenza deaths Although most people recover from influenza without the need of medical care, influenza and pneumonia are still major causes of death in the United States. Influenza is a common cause of pneumonia and cases in which influenza develops into pneumonia tend to be more severe and more deadly. However, the impact of influenza varies from year to year depending on which viruses are circulating. For example, during the 2017-2018 flu season around 52,000 people died due to influenza, whereas in 2023-2024 total deaths amounted to 28,000. Preventing death The most effective way to prevent influenza is to receive an annual influenza vaccination. These vaccines have proven to be safe and are usually cheap and easily accessible. Each year, flu vaccinations prevent thousands of influenza cases, hospitalizations and deaths. It was estimated that during the 2022-2023 flu season, vaccinations prevented the deaths of around 2,479 people aged 65 years and older.

Deaths involving coronavirus disease 2019 (COVID-19) and pneumonia reported to NCHS by jurisdiction of occurrence, place of death, and age group.

Context:

From World Health Organization - On 31 December 2019, WHO was alerted to several cases of pneumonia in Wuhan City, Hubei Province of China. The virus did not match any other known virus. This raised concern because when a virus is new, we do not know how it affects people.

So daily level information on the affected people can give some interesting insights when it is made available to the broader data science community.

Johns Hopkins University has made an excellent dashboard using the affected cases data. Data is extracted from the google sheets associated and made available here.

Edited:

Now data is available as csv files in the Johns Hopkins Github repository. Please refer to the github repository for the Terms of Use details. Uploading it here for using it in Kaggle kernels and getting insights from the broader DS community.

Content

2019 Novel Coronavirus (2019-nCoV) is a virus (more specifically, a coronavirus) identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. Early on, many of the patients in the outbreak in Wuhan, China reportedly had some link to a large seafood and animal market, suggesting animal-to-person spread. However, a growing number of patients reportedly have not had exposure to animal markets, indicating person-to-person spread is occurring. At this time, it’s unclear how easily or sustainably this virus is spreading between people - CDC

This dataset has daily level information on the number of affected cases, deaths and recovery from 2019 novel coronavirus. Please note that this is a time series data and so the number of cases on any given day is the cumulative number.

The data is available from 22 Jan, 2020.

Here’s a polished version suitable for a professional Kaggle dataset description:

Dataset Description

This dataset contains time-series and case-level records of the COVID-19 pandemic. The primary file is covid_19_data.csv, with supporting files for earlier records and individual-level line list data.

Files and Columns

1. covid_19_data.csv (Main File)

This is the primary dataset and contains aggregated COVID-19 statistics by location and date.

• Sno – Serial number of the record
• ObservationDate – Date of the observation (MM/DD/YYYY)
• Province/State – Province or state of the observation (may be missing for some entries)
• Country/Region – Country of the observation
• Last Update – Timestamp (UTC) when the record was last updated (not standardized, requires cleaning before use)
• Confirmed – Cumulative number of confirmed cases on that date
• Deaths – Cumulative number of deaths on that date
• Recovered – Cumulative number of recoveries on that date

2. 2019_ncov_data.csv (Legacy File)

This file contains earlier COVID-19 records. It is no longer updated and is provided only for historical reference. For current analysis, please use covid_19_data.csv.

3. COVID_open_line_list_data.csv

This file provides individual-level case information, obtained from an open data source. It includes patient demographics, travel history, and case outcomes.

4. COVID19_line_list_data.csv

Another individual-level case dataset, also obtained from public sources, with detailed patient-level information useful for micro-level epidemiological analysis.

✅ Use covid_19_data.csv for up-to-date aggregated global trends.

✅ Use the line list datasets for detailed, individual-level case analysis.

Country level datasets:

If you are interested in knowing country level data, please refer to the following Kaggle datasets:

India - https://www.kaggle.com/sudalairajkumar/covid19-in-india

South Korea - https://www.kaggle.com/kimjihoo/coronavirusdataset

Italy - https://www.kaggle.com/sudalairajkumar/covid19-in-italy

Brazil - https://www.kaggle.com/unanimad/corona-virus-brazil

USA - https://www.kaggle.com/sudalairajkumar/covid19-in-usa

Switzerland - https://www.kaggle.com/daenuprobst/covid19-cases-switzerland

Indonesia - https://www.kaggle.com/ardisragen/indonesia-coronavirus-cases

Acknowledgements :

Johns Hopkins University for making the data available for educational and academic research purposes

MoBS lab - https://www.mobs-lab.org/2019ncov.html

World Health Organization (WHO): https://www.who.int/

DXY.cn. Pneumonia. 2020. http://3g.dxy.cn/newh5/view/pneumonia.

BNO News: https://bnonews.com/index.php/2020/02/the-latest-coronavirus-cases/

National Health Commission of the People’s Republic of China (NHC): http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml

China CDC (CCDC): http://weekly.chinacdc.cn/news/TrackingtheEpidemic.htm

Hong Kong Department of Health: https://www.chp.gov.hk/en/features/102465.html

Macau Government: https://www.ssm.gov.mo/portal/

Taiwan CDC: https://sites.google....

Among COVID-19 patients in the United States from February 12 to March 16, 2020, estimated case-fatality rates were highest for adults aged 85 years and older. Younger people appeared to have milder symptoms, and there were no deaths reported among persons aged 19 years and under.

Tracking the virus in the United States The outbreak of a previously unknown viral pneumonia was first reported in China toward the end of December 2019. The first U.S. case of COVID-19 was recorded in mid-January 2020, confirmed in a patient who had returned to the United States from China. The virus quickly started to spread, and the first community-acquired case was confirmed one month later in California. Overall, there had been approximately 4.5 million coronavirus cases in the country by the start of August 2020.

U.S. health care system stretched California, Florida, and Texas are among the states with the most coronavirus cases. Even the best-resourced hospitals in the United States have struggled to cope with the crisis, and certain areas of the country were dealt further blows by new waves of infections in July 2020. Attention is rightly focused on fighting the pandemic, but as health workers are redirected to care for COVID-19 patients, the United States must not lose sight of other important health care issues.

This dataset explores the relationship between the Air Quality Index (AQI) and death rates from respiratory illnesses in the United States from 2000 to 2019. It includes detailed data on AQI levels, ranging from good to hazardous, alongside corresponding mortality rates caused by conditions such as asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. The dataset covers counties across the entire United States, providing a geographically comprehensive analysis. By examining trends over two decades, this dataset offers valuable insights into how air quality impacts respiratory health outcomes nationwide.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

According to Cognitive Market Research, the Global Pneumococcal Vaccines Market Size was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

The Pneumococcal Vaccines market will expand significantly by XX% CAGR between 2024 and 2031.
The Pneumococcal Conjugate vaccine type accounts for the largest market share and is anticipated to a healthy growth over the approaching years.
The usage of the Prevenar13 pneumococcal vaccine holds the largest market share compared to others.
By Distribution channel, the public health agencies hold the largest market share compared to others.
North-America region dominated the market and accounted for the highest revenue of XX% in 2022 and it is projected that it will grow at a CAGR of XX% in the future.

Factors Affecting the Growth of the Pneumococcal Vaccines Market

The rising cases of pneumonia are directly driving the demand for pneumococcal vaccines in the market.

Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae, as called pneumococcus. There are more than 100 subtypes and most of the subtypes can cause disease, but only a few produce the majority of invasive pneumococcal infections. Pneumonia is the single largest infectious cause of death in children worldwide. It causes more than a million hospitalizations and more than 50,000 deaths each year. (Source: https://www.lung.org/lung-health-diseases/lung-disease-lookup/pneumonia/five-facts-you-should-know)

Around 4,000 cases of pneumococcal bacteremia occur every year in the United States. Bacteremia is the most common clinical presentation among children aged two years and younger, accounting for 70% of invasive disease in this group. Additionally, there are an estimated 2,000 cases of pneumococcal meningitis every year. Considering the criticality, pneumococcal disease is a serious disease that causes much sickness and death. Around, 30,300 cases and 3,250 deaths from invasive pneumococcal diseases are estimated to have occurred in the United States in 2019. (Source: https://www.immunize.org/wp-content/uploads/catg.d/p4213.pdf)

Furthermore, pneumonia accounts for around 14% of all deaths of children under 5 years old, killing nearly 740,180 children in 2019. (Source: https://www.who.int/news-room/fact-sheets/detail/pneumonia)

Certain medical concerns associated with the pneumococcal vaccine may restrict the Pneumococcal Vaccines Market growth.

Normally, most people who get a pneumococcal vaccine do not have any serious problems with it; however, with any medicines and vaccines, chances of being caught to certain side effects are always there. The side effects tend to be mild and go away on their own within a few days; however, some serious reactions might be possible.

Mild problems related to PCV15, PCV20, or PPSV23 can include Redness, swelling, pain, or tenderness where the shot was given, Fever or chills, Loss of appetite, Fussiness, Feeling tired, Headache, Muscle ache, or joint pain. These symptoms may lead people to avoid the vaccination, resulting in the restriction in the market growth. (Source: https://www.cdc.gov/vaccines/vpd/pneumo/public/index.html)

The most common side effects from pneumococcal vaccines are mild and last for 1 or 2 days. The chances of getting severe allergic reactions are very rare.; however, such independent risk factors can restrict the market growth for pneumococcal vaccines.

An innovative financial mechanism by the Pneumococcal Advance Market Commitment can be considered as an opportunity for vaccine makers to produce vaccines at affordable prices.

Each year, pneumococcal disease takes the lives of half a million children under five years of age, making it the leading vaccine-preventable cause of death among young children. The most effective estimate to prevent these deaths is to ensure access to effective, safe, and affordable vaccines. To make this happen, a pneumococcal Advance Market Commitment (AMC) has been designed to protect children against pneumococcal disease.

This financial commitment offers an innovative funding mechanism with the help of donor commitments, that can benefit vaccine makers to produce suitable and affordable vaccines for the world’s poorest countries accelerating the global roll-out of a vaccine against the world’s leading cause of child...

As of November 11, 2022, almost 96.8 million confirmed cases of COVID-19 had been reported by the World Health Organization (WHO) for the United States. The pandemic has impacted all 50 states, with vast numbers of cases recorded in California, Texas, and Florida.

The coronavirus in the U.S. The coronavirus hit the United States in mid-March 2020, and cases started to soar at an alarming rate. The country has performed a high number of COVID-19 tests, which is a necessary step to manage the outbreak, but new coronavirus cases in the U.S. have spiked several times since the pandemic began, most notably at the end of 2022. However, restrictions in many states have been eased as new cases have declined.

The origin of the coronavirus In December 2019, officials in Wuhan, China, were the first to report cases of pneumonia with an unknown cause. A new human coronavirus – SARS-CoV-2 – has since been discovered, and COVID-19 is the infectious disease it causes. All available evidence to date suggests that COVID-19 is a zoonotic disease, which means it can spread from animals to humans. The WHO says transmission is likely to have happened through an animal that is handled by humans. Researchers do not support the theory that the virus was developed in a laboratory.